Skip to Content

'
Curtis A. Pettaway, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Biologist, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Department of Urology
Unit Number: 1373
Houston, TX 77030
Phone: (713) 792-3250
Fax: (713) 794-4824
Email: cpettawa@mdanderson.org

Education & Training

Degree-Granting Education

1983 Temple University School of Medicine, Philadelphia, PA, MD, Medicine
1978 Millersville University, Millersville, PA, BA, Biology

Postgraduate Training

7/1991-6/1993 Fellowship in Urologic Oncology, Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Isaiah Fidler DVM, PhD, Research Mentor; Andrew C. von Eschenbach, MD, Clinical Mentor
7/1987-6/1991 Urology Residency, Urology, The University of Texas Southwestern Medical School, Dallas, TX, Paul C. Peters, MD
7/1986-6/1987 Surgical Residency, Surgery, Parkland Memorial Hospital, Dallas, TX, William Fry, MD
7/1984-6/1986 Postdoctoral Research Fellow, Internal Medicine, The University of Texas Health Science Center, Dallas, TX, Peter Stastny
7/1983-6/1984 Surgical Residency, Surgery, Parkland Memorial Hospital, Dallas, TX, William Fry, MD

Board Certifications

1/1995 American Board of Urology

Experience/Service

Academic Appointments

Associate Professor, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1999-8/2006
Associate Professor, Department of Cancer Biology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1999-8/2006
Assistant Professor, Department of Cancer Biology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1998-8/1999
Assistant Professor, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1994-8/1998
Faculty Associate, Department of Urology, UT M. D. Anderson Cancer Center, Houston, TX, 9/1993-8/1994

Administrative Appointments/Responsibilities

Medical Director, The University of Texas M. D. Anderson Cancer Center Prostate Outreach Project, Houston, TX, 2003-present

Other Appointments/Responsibilities

GU Task Force, American Joint Committee on Cancer (AJCC), Chicago, IL, 1/2007-present
REDUCE Steering Committee, GlaxoSmithKline, Durham, NC, 1/2004-present
Board Member, Walden, Addison, TX, 11/2001-1/2005
2002 Gertrude B. Elion Research Selection Committee, American Association for Cancer Research, Philadelphia, PA, 9/2001
Prostate Cancer Committee, American Cancer Society, Atlanta, GA, 1/1996-present
Prostate Cancer Prevention Trial Data and Safety Monitoring Committee, NCI/SWOG, Bethesda, MD, 1/1996-1/2004
Board of Directors, American Cancer Society, Atlanta, GA, 1/1994-1/1999

Institutional Committee Activities

Member, Division of Cancer Prevention Chair Search Committee, 6/2006-5/2007
Member, Infectious Disease Chair Search Committee, 1/2003-1/2005
Member, Health Disparities Chair Search Committee, 1/2003-1/2005
Co-Chair, Internal Scientific Advisory Committee to Center for Research on Minority Health, 12/2001
Member, Clinical Cancer Prevention Steering Committee, 9/2001
Selection Committee, Faculty Achievement Award, Patient Care, 1/2001
Member, Prostate Cancer Guidelines Committee, 12/2000
Member, Division of Surgery Promotions Committee, 9/2000
Selection Committee, Faculty Achievement Award, Clinical Research, 1/2000
Section Head of Cardiology, Search Committee, 1/2000
Member, Center for Research on Minority Health, Prostate Committee, 1/2000
Judges Panel, Trainee Recognition Day, 1/1999
Member, Faculty Compensation and Retention Committee, 1/1998
Member, Faculty Achievement Award, Cancer Prevention, Selection Committee, 1/1998
Member, Steering Committee on Cancer and Minorities, 1/1998
Medical Advisor, Prostate Cancer Outreach Initiative, 1/1998
Institutional Review Board, Clinical Research Committee, 1/1997-1/2000
Junior Faculty Member, Presidential Search Committee, 1/1995

Honors and Awards

2008 American Leading Doctors., Black Enterprise Magazine
2006 Citizen of the Year Award, Rho Beta Beta Chapter of Omega Psi Phi Fraternity, Inc.
2004 Certificate of Appreciation, St. Andrews United Methodist Church
2004 Minerva Award for Community Service in Physical and Mental Health, Delta Sigma Theta Sorority Inc., Houston Metropolitan Chapter
2004 Note of Appreciation Award, The Community of Faith Health & Fitness Fair
2000 Harold P. Freeman Award, American Cancer Society Texas Division
1998 Award for Prostate Cancer Education in the African American Community, 100 Black Men of Houston
1997 Achievement Award, Partners in Courage Benefiting the American Cancer Society
1997 Faculty Excellence Award, UT M. D. Anderson Cancer Center
1996 Distinguished Service Award, Houston Chapter of the 100 Black Men Male Call Celebrity Prostate Cancer Fund-Raiser
1995 Runner-Up, Society of Basic Urologic Research Essay Contest
1991 Scholar, American Foundation of Urologic Diseases Scholar
1991 Vernie Stembridge Pathology Award, The UT Southwestern Medical Center
1983 Department of Urology Award, UT M. D. Anderson Cancer Center
1983 Honors Graduate, Temple University School of Medicine
1983 I.A. Burnett Award, The Department of Urology Award
1983 Merit Scholar, Henry J. Kaiser Family Foundation Merit Scholar

Selected Publications

Peer-Reviewed Original Research Articles
1. Chen, H, Liakou CI, Kamat, A, Pettaway, CA, Ward, JF, Tang, DN, Sun, J, Jugbluth, AA, Troncoso, P, Logothetis, C, Sharma, P. Anti CTLA-4 therapy results in higher CD$+ICOShi T cell frequency and IFN-y levels in both nonmalignant and malignant prostate tissues. PNAS 106(8):2729-2734, 2/2009.
2. Pettaway CA, Horenblas S. Penile Cancer: Incremental Insights into Etiology, Diagnosis, Staging and Management. Wold Journal of Urology. e-Pub 1/2009.
3. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway P, Vijayakumar S, Weinrich S, Fubert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA. Association of HPC2/ELAC2 and RNASEL Non-Synonymous Variants With Prostate Cancer Risk in African American Familial and Sporadic Cases. The Prostate 68(16):1790-1797, 12/2008.
4. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to e-cadherin expression level: prognostic significance of mRNA and protein expression among African American prostate cancer patients. The Prostate 68(13):1467-1476, 9/2008.
5. Strom SS, Yamamura Y, Forman MR, Pettaway CA, Barrera SL, DiGiovanni J. Saturated Fat Intake Predicts Biochemical Failure after Prostatectomy. International Journal of Cancer 122(11):2581-2585, 6/2008.
6. Strom SS, Yamamura Y, Flores-Sandoval FN, Pettaway, CA, Lopez, DS. Prostate Cancer in Mexican-Americans: Identification of Risk Factors. Prosate 68(5):563-570, 4/2008.
7. Cooksley CD, Avritscher EBC, Grossman HB, Sabichi AL, Dinney CP, Pettaway CA, Elting LS. Clinical Model of Cost of Bladder Cancer in Elderly. Oncology 71(3):519-525, www.sciencedirect.com/science/article/B6VJW-4S1T0m4-1B/2/c5fbac54e58f069518b3dbaeabf02e5, 3/2008.
8. Cardenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting L. Gender and Age Differences in Blood Utilization and Length of Stay in Radical Cystectomy: A Population-based Study. Journal of Urology. e-Pub 3/2008.
9. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant Transformation of Testicular Teratoma: A chemoresistant Phenotype. Urol Oncol. e-Pub 1/2008.
10. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do K, Davuluri R, Tu S, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 110(8):1729-1737, 10/2007.
11. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ Preservation for Muscle-invasive Bladder Cancer by Transurethral Resection. Urology 70(3):473-476, 9/2007.
12. Weinrich S, Vijayakumar S, Powell IJ, Hamner CA, McCloud L, Pettaway C. Knowledge of Hereditary Prostate Cancer among HIgh-Risk African American Men. Oncology Nursing Forum 34(4):854-60, 7/2007.
13. Brown GA, Matin SF, Busby JE, Dinney CPN, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Adult Urology 70(2):252-256, 3/2007.
14. Efsthiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-1231, 2/2007.
15. Baffoe-Bonnie AB, Kittles RA, Gillanders E, Ou L, George A, Robbins C, Moses T, Ahaghotu C, Bennett J, Boykin W, Hoke G, Mason T, Pettaway C, Vijayakumar S, Weinrich S, Jones MP, Lockwood E, Klaric M, Faruque M, Royal C, Trent JM, Berg K, Collins FS, Furbert-Harris P, Bailey-Wilson JE, Dunston G, Powell I, Carpten JD. Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer Study (AAHPC). The Prostate 67(1):22-31, 1/2007.
16. Carmack-Taylor CL, deMoor C, Basen-Engquist K, Smith MA, Dunn Al, Badr H, Pettaway C, Gritz ER. Moderator analyses of participants in the Active for Life after Cancer trial: implications for physical activity group intervention studies. Annals of Behavioral Medicine 33(1):99-104, 2007.
17. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. Journal of Urology 177(4):1335-38, 2007.
18. Spiess PE, Izawa JI, Bassett R, Kedar D, Busby JE, Wong F, Eddings T, Tamboli P, Pettaway CA. Pre-operative lymphoscintigraphy and dynamic sentinel node biopsy in staging penile cancer: results with pathologic correlation. Journal of Urology 177(6):2157-61, 2007.
19. Leibovici D, Spiess PE, Agarwal PK, Tu S, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate Cancer Progression in the Presence of Undetectable or Low Serum Prostate-Specific Antigen Level. Cancer 109(2):198-204, 2007.
20. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Pettaway CA. Randomized prospective trial evaluating testosterone, hemoglobin kinetics, and quality of life during and after 12 months of post-prostatectomy androgen deprivation. Results from the Postoperative Adjuvant Androgen Deprivation (PAAD) Trial. BJU 100(1):63-69, 2007.
21. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient-reported continence outcomes at 32 months. Journal of Urology 177(6):2200-04, 2007.
22. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98:1176-80, 12/2006. PMID: 17125474.
23. Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15:847-62, 10/2006. PMID: 16447306.
24. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176:1463-7, 10/2006. PMID: 16952661.
25. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107:75-82, 7/2006. PMID: 16736511.
26. Cardenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 108:169-75, 7/2006. PMID: 16816072.
27. Anai S, Wludyka P, Pendleton J, Williams C, Nelms L, Pettaway CA, Rosser CJ. Prostate cancer screening and detection in inner-city and underserved men. JNMA 98(4):515-19, 4/2006.
28. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312:584-93, 3/2006. PMID: 16445911.
29. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway CA, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43(6):507-511, 2006.
30. Weinrich S, Weinrich M, Pettaway CA, Vijayakumar S, Powell IJ, Bennett JK, Ahaghotu CA, Hoke G, Mason T, Boykin WH, Priest J, Roberson-Smith, Frost J, Meegan C, Johnson E, Faison-Smith L, Atkinson C, Robertson T, Smith S, Mejia R, Royal C, Mensah E, Kittles R, Trent J, Carpten J, Berg K, Bailey-Wilson J, Baffoe-Bonnie A, Collins F, Dunston G. Prostate Cancer Screening in High Risk Men. Cancer 106(4):796-803, 2006.
31. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174:2186-90, 12/2005. PMID: 16280761.
32. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889-94, 10/2005. PMID: 16203779.
33. Eltin LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EBC, Saldin K, Dinney CPN. Correlation between annual volume of cystectomy, professional staffing, and outcomes. Cancer 104(5):975-84, 9/2005.
34. Busby JE, Pettaway CA. What's new in the management of penile cancer? Curr Opin Urol 15:350-7, 9/2005. PMID: 16093861.
35. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14:1697-702, 7/2005. PMID: 16030104.
36. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11:4512-20, 6/2005. PMID: 15958637.
37. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64:40-9, 6/2005. PMID: 15651067.
38. Sanchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 173:1958-65, 6/2005. PMID: 15879790.
39. Izawa J, Kedar D, Wong F, Pettaway CA. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol 12 Suppl 1:24-9, 2/2005. PMID: 15780161.
40. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62:101-4, 2005. PMID: 15389800.
41. Wyatt RB, Sanchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 12/2004. PMID: 15622688.
42. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 9/2004. PMID: 15264247.
43. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59(2):167-76, 5/2004. PMID: 15042617.
44. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, 5/2004. PMID: 15076299.
45. Sanchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 22(3):236-44; discussion 244-5, 5/2004. PMID: 15271324.
46. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 4/2004. PMID: 15102659.
47. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2 alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 64:631-638, 2004.
48. Ahaghotu C, Baffoe-Bonney A, Kittles R, Pettaway C, Powell I, Royal C, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F. Clinical characteristics of the African-American Hereditary Prostate Cancer (AAHPC) Study Cohort. Prostate Cancer and Prostatic Diseases 7:165-169, 2004.
49. Carmack-Taylor CL, Smith MA, DeMoor C, Dunn AL, Pettaway CA, Sellin R, Charnsangavej C, Hansen MC, Gritz ER. Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Control Clin Trials 25:265-285, 2004.
50. Rosser CJ, Kuban DA, Lee S-J, Levy LB, Pettaway C, Kamat AM, Chickakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96:939-944, 2004.
51. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, 11/2003. PMID: 14532792.
52. Sanchez-Ortiz RF, Pettaway CA. Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach. Urol Clin North Am 30(4):853-67, 11/2003. PMID: 14680320.
53. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, 11/2003. PMID: 14532795.
54. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
55. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9(6):2185-94, 6/2003. PMID: 12796385.
56. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2:835-843, 2003.
57. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-24, 8/2002. PMID: 12171905.
58. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 5/2002. PMID: 12173328.
59. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol 167(4):1638-42, 4/2002. PMID: 11912379.
60. Weinrich S, Royal C, Pettaway CA, Dunston G, Faison-Smith L, Priest JH, Roberson-Smith P, Frost J, Jenkins J, Brooks KA, Powell I. Interest in genetic prostate cancer susceptibility testing among african American men. Cancer Nurs 25(1):28-34, 2/2002. PMID: 11838717.
61. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8(5):1253-1265, 2002.

Invited Articles
1. Pettaway, CA, Lynch D. Contemporary Surgical Management of the Inguinal Region. AUA Update Series Lesson 33(XXI), 2002.

Editorials
1. Pettaway, CA, Horenblas S. Penile Cancer: Incremental Insights Into Etiology, Diagnosis, Staging and Management. World Journal of Urology 27(2):139, 3/2009.
2. Pettaway CA. Editorial Comment: The isolated gamma probe technique for sentinel node penile carcinoma detection is unreliable. International Brazilian Journal of Urology 33(1):58-67, 2007.
Other Articles
1. Pettaway CA. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. UroToday.com, 5/2007.

Abstracts
1. Black PC, Basen-Engquist K, Wang X, Eddings T, Pettaway CA. Testosterone, hemoglobin kinetics and quality of life during and after 12 months of post-prostatectomy androgen deprivation. Results from the Postoperative Adjuvant Androgen Deprivation (PAAD) Trial. Journal of Urology 175(4) Suppl:#684, 2006.

Book Chapters
1. Pettaway CA, Lynch DF, Davis JW. Tumors of the Penis. In: Campbell's Urology, 9th. Ed(s) LR Kavoussi, AC Novick, AW Partin, CA Peters, AJ Wein. Saunders Elsevier: Philadelphia, 959-992, 2007.

Grant & Contract Support

Title: Center for Research on Minority Health, Prostate Cancer and Health Disparities Research
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Duration: 9/30/2006 - 8/31/2007
 
Title: UT M. D. Anderson Cancer Center SPORE in Genitourinary Cancers
Funding Source: NIH
Role: Administrative Core/Director Minority Recruitment
Principal Investigator: Colin Dinney, MD
Duration: 9/1/2006 - 8/31/2011
 
Funding Source: Center for Disease Control (CDC)
Role: Co-Investigator
Duration: 11/2/2005 - present
 
Title: Listen Up II! Prostate Cancer Awareness Through Education
Funding Source: Texas Cancer Council
Role: Principal Investigator
Duration: 9/1/2005 - 8/31/2006
 
Title: A New Video to Educate Diverse Texas Populations about Prostate Cancer, Prevention, Early Detection, and Treatment
Funding Source: Texas Cancer Council
Role: Principal Investigator
Duration: 3/1/2005 - 8/31/2005
 
Title: Multiparameter Comparison of Participants Undergoing Prostate Cancer Detection Testing in Two Different M. D. Anderson Cancer Center Programs
Funding Source: UT M. D. Anderson Cancer Center Prostate Cancer Research Program
Role: Principal Investigator
Duration: 9/1/2004 - 8/31/2005
 
Title: Determining the Invasive Index in Prostate Biopsy and Radical Prostatectomy Specimens as Determined by the Matrix Metalloproteinase to E-cadherin Ratio, No-Cost Extension
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 1/12/2004 - 2/11/2008
 
Title: Prostate Outreach Project (POP), No-Cost Extension
Funding Source: The University of Texas M. D. Anderson Cancer Center
Role: Principal Investigator
Duration: 10/10/2003 - 9/30/2004
 
Title: TGF-beta 1-Regulated IL-8 Expression in Prostate Cancer, No-Cost Extension
Funding Source: NIH
Role: Co-Investigator
Duration: 4/1/2003 - 3/31/2008
 
Title: Centers for Disease Control and Prevention, No-Cost Extension
Funding Source: Satellite Clinic AKA MDACC Prostate Outreach Project
Role: Principal Investigator
Duration: 9/30/2002 - 9/29/2005
 
Title: UT M. D. Anderson Cancer Center SPORE in Genitourinary Cancers, No-Cost Extension
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Colin Dinney, MD
Duration: 7/1/2001 - 6/30/2006
 
Title: Molecular Therapeutics for Advanced Prostate Cancer that Target Protein Kinase C-Dependent Mechanisms of MAP Kinase Activation, No-Cost Extension
Funding Source: NIH (O'Brien)
Role: Co-Investigator
Duration: 7/1/2001 - 6/30/2003
 
Title: SPORE in Prostate Cancer-Clinical, Epidemiological, and Molecular Markers of Prostate Cancer Progression, No-Cost Extension
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Christopher Logothetis, MD
Duration: 4/1/2001 - 12/31/2007
 
Title: Training of Academic Urologic Oncologists, No-Cost Extension
Funding Source: NCI
Role: Co-Investigator
Duration: 8/1/2000 - 6/30/2010
 
Title: Prostate Cancer in Mexican-Americans and African-Americans, No-Cost Extension
Funding Source: NIH
Role: Co-Investigator
Duration: 4/1/2000 - 3/30/2005
 
Title: Angiogenesis Regulates Prostate Cancer Metastasis, No-Cost Extension
Funding Source: United States Army Department of Defense
Role: Principal Investigator
Duration: 9/1/1998 - 2/28/2001
 
Title: Pre-surgical Stress Reduction, Mental Health, and Cancer, No-Cost Extension
Funding Source: NIMH/NCI
Role: Co-Investigator
Duration: 4/1/1998 - 6/30/2003
 
Title: A Physical Activity QOL Intervention for Androgen Ablated Prostate Cancer, No-Cost Extension
Role: Co-Investigator
Duration: 1/1/1998 - 12/31/2000
 
Title: The Proteasome as a New Drug Target in Metastatic Prostate Cancer, No-Cost Extension
Role: Co-Investigator
Duration: 1/1/1998 - 1/1/1999
 
Title: African American Hereditary Prostate Cancer Program, No-Cost Extension
Funding Source: NIH/Wayne State University
Role: Principal Investigator
Duration: 10/1/1997 - 7/30/2003
 
Title: The Molecular Determinants of Prostate Cancer Metastasis, No-Cost Extension
Funding Source: Robert Wood Johnson Foundation
Role: Principal Investigator
Duration: 7/1/1997 - 6/30/2001

Last updated: 6/24/2009